High Times
Home > Boards > Canadian > Medical - Drugs >

BriaCell Therapeutics (bctxf)

bctxf RSS Feed
Add BCTXF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/4/2018 9:16:56 AM - Followers: 5 - Board type: Free - Posts Today: 0

http://briacell.com/

WebSite
About BriaCell

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based vaccine technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.

In a preliminary Phase I clinical study in metastatic (i.e., Stage IV) breast cancer patients who had failed multiple treatments, Bria-IMT™ treatment significantly reduced the tumor size, without serious side effects. Importantly, the tumor regression was observed in other sites including the lung and even the brain -a difficult site. Impressively, the median lifespan of the patients was substantially longer than that of the comparable trials.

At our laboratory facility in Berkeley, CA, we are planning to expand our pipeline of oncology immunotherapy candidates using our proprietary technology platform.

Using the clinical data from the patients from the clinical studies, we are working to identify the molecular fingerprint of the patients for which the vaccine would be highly effective, and are planning to develop diagnostic testing products to identify this group. By directing the drug to the top-responders, we expect this approach to increase the likelihood of clinical trial success of Bria-IMT™ -to bring hope to thousands of cancer patients with few-to-no treatment options.

The company is currently recruiting its Phase I/IIa trial to further test Bria-IMT™ safety and activity in metastatic breast cancer patients. BriaCell maintains global rights for Bria-IMT™.

Phase I/IIa Clinical Study of Bria-IMT™ in Advanced Breast Cancer

BriaCell is currently recruiting patients to evaluate the safety and activity of Bria-IMT™ in an additional Phase I/IIa study in 25-40 metastatic breast cancer patients who have failed at least one course of treatment.

For the details of the trial, please visit For the details of the trial, please visit https://www.clinicaltrials.gov/ct2/show/NCT03066947

Roll-Over Combination Therapy Study

FDA has approved the roll-over combination study of Bria-IMT™ with pembrolizumab (Keytruda; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy; manufactured by Bristol-Myers Squibb Company) for patients previously treated with BriaVax™ from the ongoing Phase I/IIa Clinical Trial in Advanced Breast Cancer. The study is available for patents on the SV-BR-1-GM Phase I/IIa study who develop progressive disease. These patients will be eligible to roll-over into combination therapy with Keytruda or Yervoy, depending on the type of breast cancer they have.

More information on the roll-over combination study of Bria-IMT™ with either ipilimumab or pembrolizumab will be available on ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03328026)

KEYTRUDA® (pembrolizumab)

Manufactured by Merck & Co., Inc., KEYTRUDA® (pembrolizumab) is a prescription medicine that may treat certain cancers by working with the immune system. It has been approved for the treatment of a number of cancer indications excluding breast cancer.

For more information on pembrolizumab, please see:
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

About YERVOY® (ipilimumab)

Manufactured by Bristol-Myers Squibb Company, YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable). It is a monoclonal antibody that works to activate the immune system and enabling them to recognize and destroy cancer cells.

For more informations on Ipilimumab, please see:
https://packageinserts.bms.com/pi/pi_yervoy.pdf

 

Clinical Development Timeline – Breast Cancer

High Times
bctxf
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#71   https://www.otcmarkets.com/stock/BCTXF/news/NetworkNewsAudio-Announces-Audio-Pre shanak10 10/04/18 09:16:56 AM
#70   https://finance.yahoo.com/news/networknewswire-announces-publication-hope-horizo shanak10 10/03/18 09:31:53 AM
#69   $BCTXF going to dabble in this one, long swing. shanak10 09/18/18 09:49:12 AM
#68   Looking good here! CREEP 06/14/18 12:53:16 AM
#67   BriaCell Publishes Clinical Findings in 2018 American Society CREEP 05/30/18 02:17:47 PM
#66   Budfoxhub - mvwise1 05/23/18 02:23:45 PM
#65   check out the $BCTXF news: BriaCell Provides Highlights budfoxhub 04/18/18 11:54:36 AM
#64   otcqb company here https://www.otcmarkets.com/stock/BCTXF/overview budfoxhub 04/18/18 09:06:35 AM
#63   .113's thin on the ask budfoxhub 04/10/18 12:27:28 PM
#62   “The results to be presented will add to budfoxhub 04/10/18 11:30:52 AM
#61   The poster will describe preliminary findings on safety budfoxhub 04/10/18 11:18:54 AM
#60   BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, budfoxhub 04/10/18 11:18:37 AM
#59   news out! BriaCell to Present Encouraging Clinical Data budfoxhub 04/10/18 09:25:38 AM
#58   Dedicated to enhance the lives of cancer patients budfoxhub 04/10/18 09:09:41 AM
#57   undervalued at these levels budfoxhub 04/10/18 08:34:38 AM
#56   solid otcqb company here https://www.otcmarkets.com/stock/BCTXF/overview budfoxhub 04/10/18 07:46:11 AM
#55   green in power hour! budfoxhub 04/03/18 03:25:52 PM
#54   Trading nicely at the HOD. BCTXF Robertscott 04/03/18 03:20:22 PM
#53   The findings detailed in the paper provide a budfoxhub 04/03/18 02:08:12 PM
#52   The peer-reviewed paper provides evidence for the unique budfoxhub 04/03/18 01:11:40 PM
#51   BERKELEY, Calif. and VANCOUVER, British Columbia, April 03, budfoxhub 04/03/18 12:28:48 PM
#50   The findings detailed in the paper provide a budfoxhub 04/03/18 11:42:28 AM
#49   Very interesting stuff for BCTXF Robertscott 04/03/18 11:08:52 AM
#48   BriaCell’s Lead Product Candidate Mechanism of Action Described budfoxhub 04/03/18 09:45:57 AM
#47   BCTXF - Briacell Investment Summary: CREEP 04/03/18 09:26:42 AM
#46   Dedicated to enhance the lives of cancer patients budfoxhub 04/03/18 09:20:47 AM
#45   Agree, a lot of upside here budfoxhub 04/03/18 09:10:32 AM
#44   Great to see you here on this board CREEP 04/03/18 08:54:44 AM
#43   BCTXF News: BriaCell’s Lead Product Candidate Mechanism of CREEP 04/03/18 08:52:59 AM
#42   .113 thin on the ask budfoxhub 04/03/18 08:52:37 AM
#41   undervalued company at these levels budfoxhub 04/03/18 08:22:25 AM
#40   solid otcqb stock here https://www.otcmarkets.com/stock/BCTXF/overview budfoxhub 04/03/18 08:22:12 AM
#39   Insider Buying: CREEP 03/23/18 11:46:53 AM
#38   Upcoming Milestones: From January 2018 CREEP 03/19/18 05:58:19 PM
#37   Huge volume the last 5 days if you CREEP 03/19/18 04:06:12 PM
#36   BriaCell Appoints Top Social Media Marketing Analyst CREEP 03/14/18 12:24:57 PM
#35   BriaCell Announces Proposed Investment by Leading Biotech Funds CREEP 03/09/18 09:50:55 AM
#34   BriaCell to Present At 2018 ROTH Conference CREEP 03/09/18 09:46:03 AM
#33   BriaCell currently is enrolling patients in two separate CREEP 03/06/18 11:57:40 AM
#32   BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-on CREEP 03/01/18 09:20:15 AM
#31   BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-on CREEP 02/06/18 11:49:17 AM
#30   riaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-onc CREEP 02/05/18 03:01:26 PM
#29   BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-on CREEP 01/04/18 05:39:17 PM
#28   One of the best ground floor bios you GimmeWater 05/13/17 05:42:32 PM
#27   First patient has been dosed. Astrodamus7 05/12/17 01:18:39 AM
#26   Great post, thank you! GimmeWater 04/23/17 07:52:02 PM
#25   INTERVIEW TRANSCRIPTS FROM THE WALL STREET ANALYZER. Astrodamus7 04/21/17 01:12:50 AM
#24   Briacell CEO is helping fund the trial with GimmeWater 03/21/17 12:54:43 PM
#23   Trial Underway! GimmeWater 03/21/17 12:53:32 PM
#22   Look at this management team! This is GimmeWater 03/15/17 10:11:06 AM
PostSubject